TY - JOUR
T1 - ShockOmics
T2 - Multiscale approach to the identification of molecular biomarkers in acute heart failure induced by shock
AU - Aletti, Federico
AU - Conti, Costanza
AU - Ferrario, Manuela
AU - Ribas, Vicent
AU - Bollen Pinto, Bernardo
AU - Herpain, Antoine
AU - Post, Emiel
AU - Romay Medina, Eduardo
AU - Barlassina, Cristina
AU - de Oliveira, Eliandre
AU - Pastorelli, Roberta
AU - Tedeschi, Gabriella
AU - Ristagno, Giuseppe
AU - Taccone, Fabio S.
AU - Schmid-Schönbein, Geert W.
AU - Ferrer, Ricard
AU - De Backer, Daniel
AU - Bendjelid, Karim
AU - Baselli, Giuseppe
PY - 2016/1/28
Y1 - 2016/1/28
N2 - Background: The ShockOmics study (ClinicalTrials.gov identifier NCT02141607) is a multicenter prospective observational trial aimed at identifying new biomarkers of acute heart failure in circulatory shock, by means of a multiscale analysis of blood samples and hemodynamic data from subjects with circulatory shock. Methods and Design: Ninety septic shock and cardiogenic shock patients will be recruited in three intensive care units (ICU) (Hôpital Erasme, Université Libre de Bruxelles, Belgium; Hospital Universitari Mutua Terrassa, Spain; Hôpitaux Universitaires de Genève, Switzerland). Hemodynamic signals will be recorded every day for up to seven days from shock diagnosis (time T0). Clinical data and blood samples will be collected for analysis at: i) T1 <16 h from T0; ii) T2 = 48 h after T0; iii) T3 = day 7 or before discharge or before discontinuation of therapy in case of fatal outcome; iv) T4 = day 100. Discussion: ShockOmics will provide new insights into the pathophysiological mechanisms underlying shock as well as new biomarkers for the timely diagnosis of cardiac dysfunction in shock and quantitative indices for assisting the therapeutic management of shock patients.
AB - Background: The ShockOmics study (ClinicalTrials.gov identifier NCT02141607) is a multicenter prospective observational trial aimed at identifying new biomarkers of acute heart failure in circulatory shock, by means of a multiscale analysis of blood samples and hemodynamic data from subjects with circulatory shock. Methods and Design: Ninety septic shock and cardiogenic shock patients will be recruited in three intensive care units (ICU) (Hôpital Erasme, Université Libre de Bruxelles, Belgium; Hospital Universitari Mutua Terrassa, Spain; Hôpitaux Universitaires de Genève, Switzerland). Hemodynamic signals will be recorded every day for up to seven days from shock diagnosis (time T0). Clinical data and blood samples will be collected for analysis at: i) T1 <16 h from T0; ii) T2 = 48 h after T0; iii) T3 = day 7 or before discharge or before discontinuation of therapy in case of fatal outcome; iv) T4 = day 100. Discussion: ShockOmics will provide new insights into the pathophysiological mechanisms underlying shock as well as new biomarkers for the timely diagnosis of cardiac dysfunction in shock and quantitative indices for assisting the therapeutic management of shock patients.
KW - Acute heart failure
KW - Biomarkers
KW - Hemodynamics
KW - Metabolomics
KW - Multiscale modeling
KW - Proteomics
KW - Shock
KW - Transcriptomics
UR - http://www.scopus.com/inward/record.url?scp=84957812815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957812815&partnerID=8YFLogxK
U2 - 10.1186/s13049-016-0197-4
DO - 10.1186/s13049-016-0197-4
M3 - Article
AN - SCOPUS:84957812815
JO - Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
JF - Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
SN - 1757-7241
ER -